NASDAQ:CODXCo-Diagnostics Stock Price, Forecast & News

Co-Diagnostics' stock was trading at $13.19 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CODX shares have increased by 28.4% and is now trading at $16.93. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Co-Diagnostics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Co-Diagnostics.

Co-Diagnostics is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Co-Diagnostics.

Co-Diagnostics Inc (NASDAQ:CODX) announced its quarterly earnings results on Thursday, May, 14th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.04) by $0.01. The firm had revenue of $1.55 million for the quarter, compared to the consensus estimate of $1.10 million. Co-Diagnostics had a negative net margin of 334.58% and a negative return on equity of 81.15%. View Co-Diagnostics' earnings history.

Co-Diagnostics updated its fourth quarter earnings guidance on Tuesday, March, 31st. The company provided earnings per share (EPS) guidance of ($0.36) for the period, compared to the Thomson Reuters consensus estimate of ($0.09). The company issued revenue guidance of $214.97 million, compared to the consensus revenue estimate of $0.10 million.

2 brokers have issued 1 year price targets for Co-Diagnostics' stock. Their forecasts range from $4.00 to $30.00. On average, they anticipate Co-Diagnostics' stock price to reach $17.00 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price. View analysts' price targets for Co-Diagnostics.

Media coverage about CODX stock has been trending somewhat negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Co-Diagnostics earned a media sentiment score of -1.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news aboutCo-Diagnostics.

Some companies that are related to Co-Diagnostics include Shockwave Medical (SWAV), Luminex (LMNX), Cardiovascular Systems (CSII), Axonics Modulation Technologies (AXNX), Silk Road Medical (SILK), Atrion (ATRI), Cerus (CERS), Tactile Systems Technology (TCMD), Cryolife (CRY), Orthopediatrics (KIDS), OraSure Technologies (OSUR), Orthofix Medical (OFIX), GenMark Diagnostics (GNMK), Vapotherm (VAPO) and SurModics (SRDX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Co-Diagnostics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Moderna (MRNA), Advanced Micro Devices (AMD), Vaxart (VXRT), Johnson & Johnson (JNJ), NVIDIA (NVDA), Micron Technology (MU) and Alibaba Group (BABA).

(CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at a price of $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities served as the underwriters for the IPO.

Co-Diagnostics trades on the NASDAQ under the ticker symbol "CODX."

Co-Diagnostics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.34%), Morgan Stanley (1.34%), Geode Capital Management LLC (0.44%), Harvest Investment Services LLC (0.24%), IFG Advisory LLC (0.22%) and Wealth Architects LLC (0.15%). View institutional ownership trends for Co-Diagnostics.

CODX stock was sold by a variety of institutional investors in the last quarter, including HighTower Advisors LLC. View insider buying and selling activity for Co-Diagnostics.

CODX stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, Geode Capital Management LLC, Harvest Investment Services LLC, IFG Advisory LLC, Wealth Architects LLC, Engineers Gate Manager LP, and Paloma Partners Management Co. View insider buying and selling activity for Co-Diagnostics.

Shares of CODX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CODX stock can currently be purchased for approximately $16.93.

Co-Diagnostics has a market capitalization of $464.90 million and generates $220,000.00 in revenue each year. The company earns $-6,200,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. Co-Diagnostics employs 22 workers across the globe.

The official website for Co-Diagnostics is www.codiagnostics.com.

Co-Diagnostics' mailing address is 2401 SOUTH FOOTHILL DRIVE SUITE D, SALT LAKE CITY UT, 84109. The company can be reached via phone at 801-438-1036 or via email at [email protected]